UAE Cancer Pain Management Market Analysis Report [2022-30]

UAE Cancer Pain Management Market Analysis

$ 3999

The UAE Cancer Pain Management market is projected to grow from $32.6 Mn in 2022 to $53.15 Mn by 2030, registering a CAGR of 6.3% during the forecast period of 2022-2030. The main factors driving the growth would be the increasing incidence of cancers, growing awareness, advanced healthcare infrastructure, and government support. The market is segmented by drug type and by disease. Some of the major players include Neopharma (ARE), NewBridge Pharmaceuticals (ARE), Abbott, Pfizer, and Johnson & Johnson.

ID: IN10AEHS002 CATEGORY: Healthcare Services GEOGRAPHY: UAE AUTHOR: Neha Davda

Buy Now

UAE Cancer Pain Management Market Executive Summary

The UAE Cancer Pain Management market is projected to grow from $32.6 Mn in 2022 to $53.15 Mn by 2030, registering a CAGR of 6.3% during the forecast period of 2022 - 2030. The UAE's national healthcare spending as a percentage of GDP increased from 4.15% in 2018 to 4.28% in 2019. The UAE government has prioritized the development of a first-rate healthcare infrastructure, and as a result, the sector has grown and developed significantly during the past several years.

Cancer itself, as well as cancer-related treatments like chemotherapy and surgery, can all result in pain. The type, location, and degree of pain experienced have an impact on the medication choice and administration. Numerous drugs can be used to treat cancer-related pain. For instance, strong opioids are used to treat severe pain, despite the fact that non-opioid medications like acetaminophen and NSAIDs are preferred to treat mild to moderate cancer pain. In UAE, the overall Age Standardized incidence rate for cancer was 78.4/ 100,000.

uae cancer pain management market analysis

Market Dynamics

Market Growth Drivers

The cancer pain management market in UAE is expected to be driven by factors such as increasing incidence of cancers, growing awareness, and government support. Moreover, the UAE's well-established healthcare system draws patients from outside seeking cancer pain management therapies, which helps the market to expand.

Market Restraints

The adverse effects of pain management drugs and regulatory challenges, such as stretched clearance procedures for new pharmaceuticals and medical devices, are the factors that will hinder the expansion of the cancer pain market in the UAE.

Competitive Landscape

Key Players

Neopharma (ARE)
NewBridge Pharmaceuticals (ARE)
Abbott
Pfizer
Johnson & Johnson

Healthcare Policies and Regulatory Landscape

The UAE has a developed healthcare system, and the government has made a number of efforts to raise the standard of healthcare in the nation. The UAE's major healthcare regulatory body, the Ministry of Health and Prevention (MOH), is in charge of establishing the laws and regulations pertaining to the treatment of cancer pain. All medical facilities, including those offering treatments for cancer pain management, must be appropriately licensed and registered, according to the MOH. It also establishes requirements for the quality level of services rendered, the use of medical equipment, and the security and effectiveness of drugs. Additionally, the MOH is in charge of approving and disseminating pharmaceutical products, and it makes sure that only medicines that adhere to its safety and efficacy requirements are sold on the market. The MOH periodically publishes data on the cost and accessibility of cancer pain management medications in an effort to foster transparency.

Reimbursement Scenario

Depending on the type of product and the patient's insurance coverage, different pain management products in the United Arab Emirates (UAE) have different reimbursement scenarios. The UAE's healthcare system, including how pain relief products are reimbursed, is governed by the Ministry of Health and Prevention (MOHP) and Dubai Health Authority (DHA). Drugs and procedures for pain management may be fully or partially covered by some insurance companies, but not by others. Private hospitals may additionally provide direct payment or other insurance choices for paying for pain management items.

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Cancer Pain Management Market Segmentation

By Drug Type (Revenue, USD Billion):

Non-steroidal anti-inflammatory medicines relieve pain at the site of injury by blocking the cyclooxygenase enzyme, which prevents prostaglandin formation. NSAIDs are a class of medications that includes medications with analgesic, antipyretic, and, at higher doses, anti-inflammatory properties.

Opioids
Morphine
- Fentanyl
- Others
Non-Opioids
Acetaminophen
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Nerve Blockers

By Disease Indication (Revenue, USD Billion):

Based on disease Indication the market is segmented into:

Lung Cancer
Colorectal cancer
Breast cancer
Prostate cancer
Blood cancer
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.